Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
April 17, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – AACR Annual Meeting 2026, Asgard Therapeutics, Gene therapies, cancer immunotherapy, in vivo direct cell reprogramming, oncology
- Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified
- AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tumor immune response to benefit cancer patients in need.
17 April 2026 — Lund, Sweden — Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it will be presenting a poster on its lead asset AT-108 at the AACR Annual Meeting, held in San Diego, California, US, from 17-22 April 2026.
AT-108 is a transformative gene therapy utilizing Asgard’s in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells. This approach forces these tumor cells to present their tumor antigens, ultimately leading to a personalized anti-tumor immune response. Asgard is progressing its first-in-class therapy toward clinical development, with a focus on solid tumors, and is advancing IND-enabling studies and CMC development.
The poster presentation, titled ‘Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent’, will detail preclinical data demonstrating that AT-108 induces systemic, dose-dependent efficacy with broad tumor activity. Key biomarker parameters were highlighted to be explored in future clinical development.
Details of the poster presentation are as follow:
Poster title: Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent
Presenter: Fabio Rosa, Asgard Therapeutics
Authors: Fritiof Åkerström, Xavier Catena, Marta Santiago, Ana Perego, Ruixian Liu, Arun Sundaramurthy, Lihan Xie, Emilie Renaud, Andreea-Medeea Matei, Xiaoli Huang, Emma Leire, Ozcan Met, Inge-Marie Svane, Shane Olwill, Cristiana Pires, Filipe Pereira, Fabio Rosa
Poster session: Session LBPO.ET04 – Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session date and time: 22 April, 2026, 9:00 AM – 12:00 PM PDT
Location: Section 53
Poster number: LB455 / 2
About Asgard Therapeutics
Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Asgard Therapeutics aims to establish a pipeline of off-the-shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Asgard is backed by Novo Holdings, Boehringer Ingelheim Venture Fund, Industrifonden, RV Invest and Johnson & Johnson Innovation – JJDC, Inc. For more information, please visit: www.asgardthx.com
